Aerovate Therapeutics 11/12/2024 Earnings Report $2.51 0.00 (0.00%) As of 04:00 PM Eastern Earnings HistoryForecast Aerovate Therapeutics EPS ResultsActual EPS-$0.56Consensus EPS -$0.59Beat/MissBeat by +$0.03One Year Ago EPSN/AAerovate Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAerovate Therapeutics Announcement DetailsQuarterDate11/12/2024TimeAfter Market ClosesConference Call ResourcesAVTE Earnings History Remove Ads Aerovate Therapeutics Earnings HeadlinesAerovate Therapeutics (AVTE) Expected to Announce Earnings on MondayMarch 22, 2025 | americanbankingnews.comSTOCKHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - NHHS, KVAC, AMPS, AVTEMarch 20, 2025 | morningstar.comPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.April 1, 2025 | Brownstone Research (Ad)$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – NHHS, KVAC, AMPS, AVTEMarch 19, 2025 | morningstar.com$TOCKHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - IPG, VTS, AVTE, MHLDJanuary 24, 2025 | markets.businessinsider.comUnusually active option classes on open January 16thJanuary 16, 2025 | markets.businessinsider.comSee More Aerovate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aerovate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aerovate Therapeutics and other key companies, straight to your email. Email Address About Aerovate TherapeuticsAerovate Therapeutics (NASDAQ:AVTE), a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.View Aerovate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
